Market Cap (In CHF)
977.96 Million
Revenue (In CHF)
320.37 Million
Net Income (In CHF)
-51.44 Million
Avg. Volume
11.09 Thousand
- Currency
- CHF
- Country
- Healthcare
- Open
- -
- Prev. Close
- -
- Day Range
- -
- Year Range
- 14.18979-29.65
- PE
- -
- EPS
- -
- Beta Value
- 1.12
- ISIN
- CH1110760852
- CUSIP
- -
- CIK
- -
- Shares
- -
- Earnings Annoncement
- -
Company Profile
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Mr. Juan Jose Gonzalez
- Employee Count
- -
- Website
- https://www.polypeptide.com
- Ipo Date
- 2021-11-12
- Details
- PolyPeptide Group AG operate as a contract development and manufacturing company worldwide. It focuses on proprietary and generic GMP-grade peptides used by pharmaceutical and biotech companies in approved pharmaceutical products, drugs in clinical development, and in generic products. It engages in manufacturing custom research grade peptides; and developing neoantigen peptide to support personalized cancer therapies. The company is also involved in manufacturing peptides for commercially approved peptide therapeutics. In addition, it manufactures peptide-based generics for human and veterinary markets; and cosmetic peptides. Further, the company offers regulatory affair support services. The company was founded in 1952 and is headquartered in Zug, Switzerland. PolyPeptide Group AG is a subsidiary of Draupnir Holding B.V.
More Stocks
-
BRSYFBrainsWay Ltd.
BRSYF
-
EGCO-R
-
LINVLendInvest plc
LINV
-
GMEGameStop Corp.
GME
-
RINO
-
VISAKAINDVisaka Industries Limited
VISAKAIND
-
NLY-PI
-
CLTNCOLTENE Holding AG
CLTN